What is Camurati-Engelmann disease

Camurati-Engelmann disease (CED), also known as progressive diaphyseal dysplasia, is a rare genetic bone disorder characterized by the abnormal thickening and hardening of the shafts of the long bones. It primarily affects the limbs, causing chronic pain, muscle weakness, and impaired mobility, and is caused by mutations in the TGFB1 gene.

What exactly is Camurati-Engelmann disease?

Camurati-Engelmann disease is a rare skeletal condition that causes the outer layer of the long bones (the diaphysis) to grow thicker and denser than normal. This process, known as hyperostosis, leads to bone pain, a "waddling" gait, and significant muscle fatigue. Because the bone marrow cavity can also be affected, individuals with Camurati-Engelmann disease may experience secondary complications related to blood cell production or nerve compression as the dense bone encroaches on surrounding tissues.

Which body systems are affected by Camurati-Engelmann disease?

While Camurati-Engelmann disease is primarily a skeletal disorder, its impact is systemic due to the chronic pain and structural changes it induces. The musculoskeletal system is most significantly impacted, with the femur, tibia, humerus, radius, and ulna being the most commonly affected areas. Beyond the bones, patients often report:

• Chronic bone pain, often described as a deep, aching sensation.


• Muscle weakness (myopathy) and wasting, which often precedes the onset of visible bone changes.


• Joint contractures, which limit the range of motion in the hips, knees, and ankles.


• Neurological symptoms, such as headaches or vision changes, if the skull base is affected by bone thickening.

How rare is Camurati-Engelmann disease and who does it affect?

Camurati-Engelmann disease is an exceptionally rare condition, with fewer than 300 cases reported in medical literature worldwide. It is inherited in an autosomal dominant pattern, meaning a child only needs to inherit one copy of the mutated gene from one parent to develop the condition. Symptoms typically manifest during childhood or adolescence, usually before the age of 30, though the severity and age of onset can vary significantly even within the same family. At DiseaseMaps.org, we have seen a community of 107 people with Camurati-Engelmann disease join our platform, highlighting the importance of shared experiences in managing this rare diagnosis.

What causes Camurati-Engelmann disease at the genetic level?

The underlying mechanism of Camurati-Engelmann disease involves mutations in the TGFB1 gene. This gene provides instructions for producing a protein that regulates cell growth, differentiation, and the formation of bone tissue. In individuals with Camurati-Engelmann disease, this protein becomes overactive, signaling the body to produce excessive amounts of bone tissue in the shafts of the long bones. This constant, uncontrolled bone remodeling is what distinguishes this condition from other sclerosing bone disorders.

How is Camurati-Engelmann disease diagnosed and managed?

Diagnosis is usually confirmed through a combination of clinical physical examination, X-ray imaging (which reveals characteristic "diaphyseal" thickening), and genetic testing to identify the TGFB1 mutation. While there is no cure, management focuses on symptom relief. Common strategies include:

1. Pharmacological management with corticosteroids or bisphosphonates to help manage pain and bone turnover.


2. Physical therapy to maintain joint flexibility and combat muscle weakness.


3. Regular monitoring by an orthopedic specialist and a geneticist.


4. Pain management programs tailored to the chronic nature of the bone pain.

Next steps

• Consult with a specialized orthopedic surgeon or a geneticist familiar with rare skeletal dysplasias.


• Connect with the 107 members of the Camurati-Engelmann disease community at DiseaseMaps.org to share coping strategies and insights.


• Keep a detailed diary of your pain levels and mobility to share with your clinical team during your next consultation.


• Request a referral to a center of excellence for rare bone diseases to ensure you are receiving the latest evidence-based care.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Camurati-Engelmann disease (ORPHA:280)


• NIH Genetic and Rare Diseases Information Center (GARD): Progressive diaphyseal dysplasia


• OMIM (Online Mendelian Inheritance in Man): #131300 - Camurati-Engelmann Disease


• PubMed: Clinical and genetic spectrum of TGFB1-associated skeletal disorders